Advertisement

Cefotetan Disodium Injection

[25 April 2016]

Products Affected - Description

Cefotetan disodium intravenous powder for solution for injection, Fresenius Kabi
10 gram vials, 1 count (NDC 63323-0396-61)

Reason for the Shortage

  • BBraun had cefotetan on allocation due to current market conditions.
  • Fresenius Kabi states the reason for the shortage is manufacturing delay.
  • Teligent received FDA approval for Cefotan in 2015.Teligent launched Cefotan in March 2016.

Available Products

Cefotan intravenous powder for solution for injection, Teligent
1 gram, vial, 10 count (NDC 52565-0052-10)
2 gram, vial, 10 count (NDC 52565-0053-10)
 
Cefotetan disodium intravenous powder for solution for injection, BBraun
1 gram/50 mL, Duplex bag, 1 count (NDC 00264-3173-11)
2 gram/50 mL, Duplex bag, 1 count (NDC 00264-3175-11)
 
Cefotetan disodium intravenous powder for solution for injection, Fresenius Kabi
1 gram, vial, 10 count (NDC 63323-0385-10)
2 gram, vial, 10 count (NDC 63323-0386-20)

Estimated Resupply Dates

Fresenius Kabi has cefotetan 10 gram vials on back order and the company estimates a release date of 3rd quarter of 2016.

Updated

April 25, March 22, 15 and 2, January 14, 2016; December 9, November 19, October 27, September 23, August 11, June 25, May 5, February 2, 2015; November 10, October 1, August 21, July 30, June 3, April 25, 2014, University of Utah, Drug Information Service. Copyright 2016, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins

Advocacy Activity
Get the latest updates on ASHP's advocacy activity on drug shortages.
Advertisement
ASHP Product Listing